AF
ALXN

Aldebaran Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Aldebaran Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,500
Closed -$426K – 98
2017
Q2 		$426K Buy
+3,500
New +$407K 0.31% 75

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aldebaran Financial's ALXN Position: Q3 2017 in Review

Aldebaran Financial sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 3,500 shares — an estimated $426K sold.

Aldebaran Financial first reported a position in ALXN in Q2 2017 and held it in 1 quarter. The position peaked at $426K in Q2 2017. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Aldebaran Financial reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Aldebaran Financial sold 3,500 Alexion Pharmaceuticals shares in Q3 2017, an estimated $426K.
  • Aldebaran Financial first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Aldebaran Financial's Alexion Pharmaceuticals position peaked at $426K in Q2 2017.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Aldebaran Financial's 13F filing for Q3 2017, filed 17 Nov 2017.